GlassScriptPhysician profile
Tamara H Perdue
NPI 1316912405
$6,400.44
in general payments reported to CMS, 2019-2025
25 companies · $2,161 in 2025
The $2,161 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,033 · 2022: $1,310 · 2023: $1,007 · 2024: $890 · 2025: $2,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,058.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,361.01 | 2021-2025 | |
| Janssen Biotech, INC. | $1,172.96 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Qol Medical, LLC | $531.49 | 2021-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $514.91 | 2021-2025 | Entyvio, Gattex |
| Celgene Corporation | $385.21 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $362.69 | 2021-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $337.82 | 2024-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $317.05 | 2021-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $145.09 | 2025 | Rezdiffra |
| Genzyme Corporation | $138.41 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $126.49 | 2024-2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $120.23 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $114.64 | 2021-2025 | Ocaliva |
| Gilead Sciences, INC. | $111.09 | 2024-2025 | |
| Pfizer INC. | $91.65 | 2023-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $91.06 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $89.73 | 2021-2022 | |
| Ardelyx, INC. | $88.24 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $73.78 | 2024-2025 | Zenpep |
| Braintree Laboratories, INC. | $66.18 | 2021-2023 | Suflave |
| Blueprint Medicines Corporation | $39.63 | 2024-2025 | Ayvakit |
| Medtronic, INC. | $39.61 | 2024-2025 | Gi Genius, Pillcam |
| Amgen INC. | $37.05 | 2021-2022 | |
| Novo Nordisk INC | $30.28 | 2025 | Wegovy |
| Lilly USA, LLC | $14.14 | 2025 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Perdue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.